keyword
MENU ▼
Read by QxMD icon Read
search

metformin antipsychotic

keyword
https://www.readbyqxmd.com/read/29713286/the-wnt-signaling-pathway-effector-tcf7l2-mediates-olanzapine-induced-weight-gain-and-insulin-resistance
#1
Ranran Li, Jianjun Ou, Li Li, Ye Yang, Jingping Zhao, Renrong Wu
Olanzapine is a widely used atypical antipsychotic medication for treatment of schizophrenia and is often associated with serious metabolic abnormalities including weight gain and impaired glucose tolerance. These metabolic side effects are severe clinical problems but the underpinning mechanism remains poorly understood. Recently, growing evidence suggests that Wnt signaling pathway has a critical role in the pathogenesis of schizophrenia and molecular cascades of antipsychotics action, of which Wnt signaling pathway key effector TCF7L2 is strongly associated with glucose homeostasis...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29620914/effects-of-metformin-on-spatial-and-verbal-memory-in-children-with-asd-and-overweight-associated-with-atypical-antipsychotic-use
#2
Michael G Aman, Jill A Hollway, Jeremy Veenstra-VanderWeele, Benjamin L Handen, Kevin B Sanders, James Chan, Eric Macklin, L Eugene Arnold, Taylor Wong, Cassandra Newsom, Rianne Hastie Adams, Sarah Marler, Naomi Peleg, Evdokia A Anagnostou
OBJECTIVES: Studies in humans and rodents suggest that metformin, a medicine typically used to treat type 2 diabetes, may have beneficial effects on memory. We sought to determine whether metformin improved spatial or verbal memory in children with autism spectrum disorder (ASD) and overweight associated with atypical antipsychotic use. METHODS: We studied the effects of metformin (Riomet® ) concentrate on spatial and verbal memory in 51 youth with ASD, ages 6 through 17 years, who were taking atypical antipsychotic medications, had gained significant weight, and were enrolled in a trial of metformin for weight management...
April 5, 2018: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29502389/second-generation-antipsychotic-and-diabetes-mellitus-in-children-and-adolescents
#3
Carlo Ripoli, Anna Paola Pinna, Faustina Podda, Roberta Zanni, Maria Giada Tronci, Anna Maria Nurchi
Second generation antipsychotics (SGA) are used in children for the treatment of various psychiatric diseases, including pervasive developmental disorders. These drugs can cause metabolic effects as hyperglycemia and diabetes. A 16-year-old young-boy, diagnosed with autism, developed diabetes mellitus type 1 whilst he was on treatment with olanzapine (started 4 months before), clomipramine, valproic acid and lithium. The hypothesis of druginduced diabetes imposed olanzapine interruption and clozapine initiation...
December 13, 2017: La Pediatria Medica e Chirurgica: Medical and Surgical Pediatrics
https://www.readbyqxmd.com/read/29486513/combination-of-metformin-and-lifestyle-intervention-for-antipsychotic-related-weight-gain-a-meta-analysis-of-randomized-controlled-trials
#4
Wei Zheng, Qing-E Zhang, Dong-Bin Cai, Xin-Hu Yang, Gabor S Ungvari, Chee H Ng, Ren-Rong Wu, Yu-Tao Xiang
INTRODUCTION: Weight gain is a common antipsychotic (AP)-related adverse drug reaction (ADR) that can increase the risk of cardiovascular diseases and premature mortality. This meta-analysis examined the efficacy and tolerability of combining metformin and lifestyle intervention for AP-related weight gain in schizophrenia. METHODS: Randomized controlled trials (RCTs) with meta-analyzable data were searched and retrieved by 2 independent investigators. RevMan software (version 5...
February 27, 2018: Pharmacopsychiatry
https://www.readbyqxmd.com/read/29389748/clinical-trials-in-autism-spectrum-disorder-evidence-challenges-and-future-directions
#5
Evdokia Anagnostou
PURPOSE OF REVIEW: The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism spectrum disorder (ASD), describe challenges in the conduct of such trials, and discuss future directions RECENT FINDINGS: Clinical trials in ASD have produced several compounds to adequately support the pharmacological treatment of associated symptom domains: attention deficit hyperactivity disorder (methylphenidate, atomoxetine, and alpha agonists), irritability/aggression (risperidone and aripiprazole), sleep (melatonin), and weight gain associated with atypical antipsychotic use (metformin)...
April 2018: Current Opinion in Neurology
https://www.readbyqxmd.com/read/29251783/effect-of-metformin-on-hypothalamic-pituitary-thyroid-axis-activity-in-elderly-antipsychotic-treated-women-with-type-2-diabetes-and-subclinical-hypothyroidism-a-preliminary-study
#6
Robert Krysiak, Witold Szkróbka, Bogusław Okopień
Metformin was found to reduce elevated serum thyrotropin levels, and this effect was partially determined by endogenous dopaminergic tone. The aim of this study was to compare the effect of metformin treatment on hypothalamic-pituitary-thyroid axis activity in elderly women with subclinical hypothyroidism treated with antipsychotic agents and not receiving this drug. The study population consisted of 34 elderly women with subclinical hypothyroidism, 16 of whom received antipsychotic drugs. Because of coexistent type 2 diabetes, these women were treated with metformin (2...
December 18, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29205415/systematic-review-human-gut-dysbiosis-induced-by-non-antibiotic-prescription-medications
#7
REVIEW
Q Le Bastard, G A Al-Ghalith, M Grégoire, G Chapelet, F Javaudin, E Dailly, E Batard, D Knights, E Montassier
BACKGROUND: Global prescription drug use has been increasing continuously for decades. The gut microbiome, a key contributor to health status, can be altered by prescription drug use, as antibiotics have been repeatedly described to have both short-term and long-standing effects on the intestinal microbiome. AIM: To summarise current findings on non-antibiotic prescription-induced gut microbiome changes, focusing on the most frequently prescribed therapeutic drug categories...
February 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29127566/monitoring-and-treating-metabolic-abnormalities-in-patients-with-early-psychosis-initiated-on-antipsychotic-medications
#8
Kevin M Bozymski, Jessica A Whitten, Mary E Blair, Ashley M Overley, Carol A Ott
Antipsychotic medications carry an established lifetime risk of metabolic syndrome. This retrospective chart review evaluated feasibility of a metabolic monitoring clinical decision support tool (CDST) for weight, lipid, blood glucose, and blood pressure management of 163 clients in an early psychosis outpatient clinic over 2 years. Each parameter had at least 98 (60.1%) clients with a recorded value, the most being documented for weight with 112 (68.7%) clients. CDST adherence ranged from at least 54.3-100% for non-pharmacologic interventions (e...
November 11, 2017: Community Mental Health Journal
https://www.readbyqxmd.com/read/28942807/a-randomized-placebo-controlled-trial-of-metformin-for-the-treatment-of-overweight-induced-by-antipsychotic-medication-in-young-people-with-autism-spectrum-disorder-open-label-extension
#9
Benjamin L Handen, Evdokia Anagnostou, Michael G Aman, Kevin B Sanders, James Chan, Jill A Hollway, Jessica Brian, L Eugene Arnold, Lucia Capano, Craig Williams, Jessica A Hellings, Eric Butter, Deepali Mankad, Rameshwari Tumuluru, Jessica Kettel, Cassandra R Newsom, Naomi Peleg, Dina Odrobina, Sarah McAuliffe-Bellin, Sarah Marler, Taylor Wong, Alexis Wagner, Stasia Hadjiyannakis, Eric A Macklin, Jeremy Veenstra-VanderWeele
OBJECTIVE: A previous study reported on a 16-week placebo-controlled, randomized clinical trial (RCT) of metformin for weight stabilization in 61 children and adolescents 6 to 17 years old with autism spectrum disorder who were prescribed atypical antipsychotics. The present study describes the results of a 16-week open-label extension. METHOD: Fifty-two participants from the acute trial (85%) entered the extension; 22 had been on metformin during the initial RCT and 30 had been on placebo...
October 2017: Journal of the American Academy of Child and Adolescent Psychiatry
https://www.readbyqxmd.com/read/28942801/antipsychotic-induced-weight-gain-and-metformin
#10
EDITORIAL
John T Walkup, Elizabeth Cottingham
No abstract text is available yet for this article.
October 2017: Journal of the American Academy of Child and Adolescent Psychiatry
https://www.readbyqxmd.com/read/28883731/antipsychotic-associated-weight-gain-management-strategies-and-impact-on-treatment-adherence
#11
REVIEW
Madhubhashinee Dayabandara, Raveen Hanwella, Suhashini Ratnatunga, Sudarshi Seneviratne, Chathurie Suraweera, Varuni A de Silva
Antipsychotic-induced weight gain is a major management problem for clinicians. It has been shown that weight gain and obesity lead to increased cardiovascular and cerebrovascular morbidity and mortality, reduced quality of life and poor drug compliance. This narrative review discusses the propensity of various antipsychotics to cause weight gain, the pharmacologic and nonpharmacologic interventions available to counteract this effect and its impact on adherence. Most antipsychotics cause weight gain. The risk appears to be highest with olanzapine and clozapine...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28747113/developing-a-metformin-prescribing-tool-for-use-in-adults-with-mental-illness-to-reduce-medication-related-weight-gain-and-cardiovascular-risk
#12
Cassie Smith, Hannah Myles, Cherrie Galletly
OBJECTIVES: There is considerable evidence that metformin reduces weight gain associated with antipsychotic medication. The aim of this study was to develop an easy-to-use metformin prescribing tool in order to enable clinicians to prescribe metformin safely and confidently. METHODS: The authors undertook a survey of clinicians and reviewed the published literature and existing guidelines concerning the use of metformin to reduce weight gain in adults with mental illness...
August 2017: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/28507773/rapid-onset-clozapine-induced-loss-of-glycaemic-control-case-report
#13
Alejandro Porras-Segovia, Amir Krivoy, Mark Horowitz, George Thomas, Mark Bolstridge, Dragos Ion, Sukhwinder S Shergill
Clozapine has proved to be an effective antipsychotic for the treatment of refractory schizophrenia - characterised by the persistence of symptoms despite optimal treatment trials with at least two different antipsychotics at adequate dose and duration - but its use is hampered by adverse effects. The development of clozapine-induced diabetes is commonly considered to arise as part of a metabolic syndrome, associated with weight gain, and thus evolves slowly. We present the case of an individual with refractory schizophrenia and metformin-controlled diabetes who developed rapid-onset insulin-dependent hyperglycaemia immediately after starting clozapine...
May 2017: BJPsych Open
https://www.readbyqxmd.com/read/28469583/commentary-a-randomized-double-blind-placebo-controlled-trial-of-metformin-treatment-of-weight-gain-associated-with-initiation-of-atypical-antipsychotic-therapy-in-children-and-adolescents
#14
COMMENT
https://www.readbyqxmd.com/read/28463344/minimizing-weight-gain-for-patients-taking-antipsychotic-medications-the-potential-role-for-early-use-of-metformin
#15
REVIEW
Victoria Hendrick, Robert Dasher, Michael Gitlin, Mehrban Parsi
BACKGROUND: Patients taking antipsychotic medications are at high risk for weight gain, which in turn leads to poor health outcomes, nonadherence with treatment, and low self-esteem. METHODS: We reviewed published studies of pharmacologic interventions aimed at minimizing antipsychotic-induced weight gain. Treatments initiated prior to onset of weight gain were compared with those that started once weight gain already had occurred. RESULTS: Although data are limited, adjunctive medications for weight management appear to be more effective when initiated at or near the time when patients are first exposed to antipsychotic medications...
May 2017: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://www.readbyqxmd.com/read/28447303/brief-report-metformin-for-antipsychotic-induced-weight-gain-in-youth-with-autism-spectrum-disorder
#16
Logan K Wink, Ryan Adams, Ernest V Pedapati, Kelli C Dominick, Emma Fox, Catherine Buck, Craig A Erickson
Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD...
July 2017: Journal of Autism and Developmental Disorders
https://www.readbyqxmd.com/read/28372526/adjunctive-metformin-for-antipsychotic-related-hyperprolactinemia-a-meta-analysis-of-randomized-controlled-trials
#17
Wei Zheng, Xin-Hu Yang, Dong-Bin Cai, Gabor S Ungvari, Chee H Ng, Nan Wang, Yu-Ping Ning, Yu-Tao Xiang
Hyperprolactinemia is a common and severe antipsychotic-induced adverse drug reaction. This meta-analysis of randomized controlled trials systematically examined the efficacy and safety of adjunctive metformin for antipsychotic-related hyperprolactinemia in schizophrenia patients. Two independent investigators searched, extracted, and synthesized data. Weighted mean differences and risk ratios with their 95% confidence intervals were calculated using random effect model. Four randomized controlled trials ( n=509) comparing adjunctive metformin ( n=253) with the control groups ( n=256), lasting 22...
May 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28347259/metformin-for-antipsychotic-induced-weight-gain-statistical-curiosities
#18
LETTER
Ekta Franscina Pinto, Biju George, Sagar Karia, Chittaranjan Andrade
No abstract text is available yet for this article.
April 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28292552/predictors-of-menstruation-restoration-during-metformin-administration-for-treatment-of-antipsychotic-drug-induced-amenorrhea-a-post-hoc-analysis
#19
Ranran Li, Jingping Zhao, Renrong Wu
No abstract text is available yet for this article.
December 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28076676/use-of-metformin-for-cardiometabolic-risks-in-psychiatric-practice-need-to-know-safety-issues
#20
Chittaranjan Andrade
Metformin, a biguanide drug, is emerging as an important treatment option for the prevention or treatment of weight gain, type 2 diabetes mellitus, and the metabolic syndrome in psychiatric patients, especially those who require or receive antipsychotic drugs. Metformin treatment is commonly associated with gastrointestinal adverse effects; the risk of these is reduced by gradual dose uptitration, administration of the drug with meals, and use of a time-release formulation. Lactic acidosis, a potentially fatal complication of biguanide therapy, is very rare with metformin; the risk can be reduced by avoidance of its prescription in patients with impaired renal function, impaired liver function, cardiac failure, and certain other conditions...
November 2016: Journal of Clinical Psychiatry
keyword
keyword
109192
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"